Researchers are seeking volunteers for a new clinical study investigating potential preventative measures against AlzheimerS disease, a condition affecting millions globally [[2]]. The Reτain study, conducted at the University Hospital of the Saarland in Homburg, germany, aims to determine if an experimental drug can delay the onset of symptoms in individuals at increased risk. Participation involves a multi-year commitment and requires a dedicated study partner, highlighting the collaborative nature of Alzheimer’s research [[1]].
Proactive Steps May Help in Alzheimer’s Disease. Clinical Research Study Seeks Participants at Risk.
Alzheimer’s disease begins to develop long before symptoms become noticeable, making early detection and intervention crucial. A new study, known as Reτain, is investigating whether an experimental drug can safely and effectively delay the onset of Alzheimer’s symptoms in individuals who are at increased risk of developing the condition. This research offers a potential pathway to slowing the progression of a disease that significantly impacts millions worldwide.
Individuals may be eligible to participate in the Reτain study if they meet the following criteria:
– Are between 55 and 75 years old,
– Are currently experiencing no cognitive, mood, or behavioral changes – meaning memory, thinking, and emotional well-being are normal.
– Have a reliable study partner available to accompany them to some study visits. This partner should be a family member, spouse, or friend aged 18 or older who has regular, weekly contact with the participant.
Those interested in learning more about the study and determining their eligibility are encouraged to contact:
The study center at the Department of Psychiatry and Psychotherapy at the University Hospital of the Saarland (UKS), 66421 Homburg,
Aline Freer, Tel. (0 68 41) 16 – 2 44 30, E-Mail: studien.psychiatrie@uks.eu
